Home Journals Articles Updates About
CN
image
收藏切换
Research progress of EGFRvⅢ targeted immunotherapy in the treatment of glioblastoma
收藏切换
PDF
Jun LIU1, 2, Shen-xia XIE2, 3, Hai-xia LI2, 4, Wei SHI2, 4, Xiao-bing JIANG5, Xuan WANG5, Xiao-mei YANG2, 4, *, Xiao-ling LU1, 2, *
Acta Pharmaceutica Sinica | 2022, 57(9) : 2662 - 2670
Less
收藏切换
Acta Pharmaceutica Sinica | 2022, 57(9): 2662-2670
• Special Reports: Therapeutic interventions and strategies for cancer immunotherapy •
Research progress of EGFRvⅢ targeted immunotherapy in the treatment of glioblastoma
Full
Jun LIU1, 2, Shen-xia XIE2, 3, Hai-xia LI2, 4, Wei SHI2, 4, Xiao-bing JIANG5, Xuan WANG5, Xiao-mei YANG2, 4, *, Xiao-ling LU1, 2, *
Affiliations
  • 1. College of Stomatology, Guangxi Medical University, Nanning 530021, China
  • 2. Guangxi Key Laboratory of Nanobody Research, Nanning 530021, China
  • 3. Pharmaceutical College, Guangxi Medical University, Nanning 530021, China
  • 4. School of Preclinical Medicine, Guangxi Medical University, Nanning 530021, China
  • 5. Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
Published: 2022-09-12 doi: 10.16438/j.0513-4870.2022-0754
Outline
收藏切换

Glioblastoma (GBM) is the most common primary brain tumor, which is prone to recurrence and metastasis with poor prognosis. In recent years, immunotherapy has prolonged the survival of patients with GBM, providing a new option for the treatment of GBM. Target selection is very important for immunotherapy. Epidermal growth factor receptor variant Ⅲ (EGFRvⅢ) is highly expressed on the surface of GBM cells in some patients, and EGFRvⅢ was not expressed in normal tissues. EGFRvⅢ are pivotal for the occurrence and progression of GBM, various targeted therapy including immunotherapy is promising to improve the efficacy of GBM. Currently, there are various approaches to target EGFRvⅢ, including humanized monoclonal antibodies, adoptive cell therapies and therapeutic vaccines. In this review, we focus on the preclinical and clinical findings of targeting EGFRvⅢ for GBM.

epidermal growth factor receptor variant Ⅲ  /  glioblastoma  /  targeted antitumor  /  immunotherapy  /  CAR-T cell  /  vaccine
Jun LIU, Shen-xia XIE, Hai-xia LI, Wei SHI, Xiao-bing JIANG, Xuan WANG, Xiao-mei YANG, Xiao-ling LU. Research progress of EGFRvⅢ targeted immunotherapy in the treatment of glioblastoma[J]. Acta Pharmaceutica Sinica, 2022 , 57 (9) : 2662 -2670 . DOI: 10.16438/j.0513-4870.2022-0754
Appendix
Less
Year 2022 volume 57 Issue 9
PDF
106
52
Cite this Article
BibTeX
Article Info
doi: 10.16438/j.0513-4870.2022-0754
  • Receive Date：2022-06-20
  • Online Date：2025-12-24
  • Published：2022-09-12
Article Data
Affiliations
History
  • Received：2022-06-20
  • Revised：2022-08-05
Funding
Affiliations
    1. College of Stomatology, Guangxi Medical University, Nanning 530021, China
    2. Guangxi Key Laboratory of Nanobody Research, Nanning 530021, China
    3. Pharmaceutical College, Guangxi Medical University, Nanning 530021, China
    4. School of Preclinical Medicine, Guangxi Medical University, Nanning 530021, China
    5. Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
References
Share
https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2022-0754
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House